|
|
 |
Company-Sponsored by OKYO Pharma* |
TODAY'S TOP ALERT! |
Nasdaq: OKYO |
|
Good morning! |
Stock futures are basically flat after yesterday's bloodletting. |
With private payrolls and jobless claims data set to drop this morning, I'm not sure what the markets have in store for us today… |
That's why I'm focused on stocks that I think have a great chance of gaining regardless of how the major indexes move. |
Yesterday, I alerted you to a double-digit winner even amid all the carnage: |
 | *Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically. |
|
23% in a day ain't bad at all, right?! |
Now, buckle up for the next one. |
My "tactical trade" idea this morning was also on the move yesterday, and I think we could see more great action today. |
Go ahead and pull up OKYO Pharma Limited (OKYO) on your trading platform. |
You'll see that the stock has been relatively stable since August, enjoying a steady ~15% runup. |
Notice it has had pretty firm support around the $1.00 mark throughout that time. |
When I last wrote to you about OKYO in October, I mentioned that I really like small-cap stocks with support at this price range due to Nasdaq's Minimum Bid Price requirement. |
That rule says if stock closes below $1.00 for 30 consecutive trading days, it falls out of compliance. |
As a result, companies listed on the Nasdaq — and their investors — tend to fight hard to stay above that range. |
That's probably why OKYO has had such a firm base of support there. |
I also like that the stock had a 5% jump yesterday, even as the broader markets tanked. |
If you recall, I have a pretty good feel for this stock. |
When I last alerted OKYO in October, it had climbed 4% the previous day even as the markets were flat. |
I sent that alert before the opening bell, and what we saw that day was nothing short of phenomenal: |
 | *Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically. |
|
Between yesterday's momentum and the stock's current level, I think this is a great one to revisit today. |
Biotechs are super hot right now, and I think OKYO could be next on the list of stocks getting investor attention on this list. |
It has had some resistance just north of where it is now, and if it pushes past that today, I think we could see a real breakout. |
On the other hand, if it drops below its support around the $1.05 level, I might wait until it inspires more confidence. |
OKYO is primed for action — make sure it tops your watchlist today! |
In the meantime, here are some notes from my research about this interesting company… |
To begin with, OKYO has an excellent website. |
I've studied tons of clinical-stage biopharma company websites, and they often get so bogged down in jargon that I don't see how they expect ordinary investors to understand what they have going on. |
Maybe that's their goal?? |
OKYO, on the other hand, does a great job of explaining their science, leadership, and investment opportunity. |
The company's main target is Dry Eye Disease (DED), which has a multibillion-dollar market (who knew? 🤷). |
DED results when the eyes don't produce enough tears, causing poor lubrication that can lead to redness, grittiness, burning, blurring, and eye fatigue. |
It's a common condition, with approximately 38 million cases in the US and 700 million cases worldwide. |
It affects over 35% of the population aged 50+, and two-thirds of DED patients are women. |
The company's lead candidate is OK-101, a topical drug designed to control inflammation and pain in the eye. |
The company has been progressing the drug rapidly. |
It began a Phase 2 trial for OK-101 as a treatment for DED in May 2023 and revealed "extremely encouraging" topline data from the trial in January last year. |
The trial found that OK-101 had a "highly favorable tolerability profile" and achieved statistical significance for multiple "sign" and "symptom" endpoints. |
Specifically, the drug proved superior to the placebo for "total conjunctival staining" — a sign of DED — and for burning/stinging and blurred vision. |
The company said that "To our knowledge, there are no FDA approved DED drugs that have been shown in clinical studies to improve conjunctival staining." |
|
OKYO now plans to advance OK-101 to a Phase 3 trial with the goal of developing a "highly differentiated dry eye product to help patients underserved by current treatments." |
In the course of the Phase 2 trial, researchers also found support for the potential of OK-101 to treat neuropathic corneal pain (NCP) — "a severe, chronic, and debilitating disease for which there are no approved commercial treatments currently available" [emphasis added] and that affects approximately 5 million people each year. |
As a result, OKYO is pursuing a parallel focus of OK-101 for that disease. |
Last February, the FDA "cleared OK-101 as its first Investigational New Drug (IND) application for the treatment of NCP" and OKYO began a Phase II trial for that purpose in October. |
The principal investigator of the trial is Dr. Pedram Hamrah of Tufts Medical Center — a renowned expert in NCP. |
As OKYO CEO Gary Jacob, Ph.D. explained in an excellent October interview, the company has a "tremendous opportunity from a commercial standpoint" by pursuing a drug to treat a major unmet medical need. This "can lead to partnerships with big pharma and the kind of final merger acquisition outcome." |
OKYO executive chairman Gabriele Cerrone — a veteran of micro-cap biotechs — has been scooping up the stock hand over fist, purchasing 50,000 shares in September, and nearly 570,000 shares in October. |
The sole analyst covering OKYO reiterated in October a 12-month price target of $7.00 — a nearly 500% increase over the stock's current price: |
|
For your own research, I recommend starting with the company's website and its corporate presentation. |
As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. |
Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration. |
Bottom line: OKYO is once again on the move even as the markets falter. The last time I saw this, the result was a 30% same-day move. |
Will we see the same sort of action today? Nothing is guaranteed, but I think this could be today's big breakout story. |
Make sure OKYO is leading your watchlist today! |
To Your Success, |
|
P.S. Make sure you join me and over 1000 traders in the Market Master's trading room today for live trading signals and education. You can access it at no cost right now. |
|
|
Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull |
|
|
*Issuer-paid advertisement: Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call "typical." |
Just a quick heads up about this ad you're reading—as we've said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we have been paid twenty five thousand dollars (cash) by bank transfer by OKYO Pharma Limited for advertising for a one day marketing program on January 8, 2025. Previously, we also received paid twenty five thousand dollars (cash) by bank transfer by OKYO Pharma Limited for advertising for a one day marketing program on October 23, 2024. Be aware that we may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case. |
Now, diving right into OKYO Pharma Limited might sound exciting. But remember, it's like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you're doing. That's why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. |
Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We're simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We're obviously biased in our writing. We're not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as "forward-L00king statements" under the securities acts, so take those with a grain of salt. As with all forecasts, they're not set in stone, often wrong, and we certainly can't know where the Company's earnings, business, or share price will be tomorrow or a year from now. |
Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, |
Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep's with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization. |
So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. |
Tidak ada komentar:
Posting Komentar